Systemic TNF blockade does not modulate synovial expression of the pro-inflammatory mediator HMGB1 in rheumatoid arthritis patients – a prospective clinical study

Table 1 Clinical assessment, response to infliximab treatment and HMGB1 expression.

Pat	W	Sex	Age (years)	Disease duration (years)	CRP	Medication		DAS28	Clinical response		HMGB1 protein		HMGB1mRNA
						MTX	Pred		DAS28	ACR	ES	CG
1	0	F	55	18	107	17.5	5 *	6.71			1.5	1
	9				38			6.34	No	0	2	1.5
2	0	F	52	6	14	7.5	7.5	6.00			1.5	1.5
	9				15			4.43	Mod	20	1	0.5	0
3	0	F	58	2	46	10		7.91			3	4
	9				25			5.41	Mod	50	1	1.5	0
4	0	F	57	4	7	10		4.94			2	2
	9				34			4.41	No	20	2	2	Up
5	0	M	56	7	44	15		5.95			2	2.5
	9				7			2.90	G	70	3.5	3
6	0	F	69	1	69	15	5	7.39			2	3
	9				7			1.79	G	70	1.5	2.5	Up
7	0	F	66	14	34	10		5.64			2	2
	9				16			4.73	Mod	0	1	0.5	Down
8	0	F	66	10	18	12.5		4.83			3.5	4
	9				19			4.23	Mod	0	0.5	2	Down
9	0	M	25	0.6	26	17.5	7.5	5.62			.5	3
	9				25			3.91	Mod	20	3	4

* Patient 1 also received 150 mg/day cyclosporine before and during the study period.Pat = Patient, W = week, CRP = C-reactive protein, MTX = Methotrexate (mg/week), Pred = Prednisone (mg/day), DAS28 = disease activity score calculated on 28 joints, ACR = American College of Rheumatology, HMGB1 = High-mobility group box chromosomal protein 1, ES = Erik Sundberg, CG = Cecilia Grundtman, F = Female, M = Male, No = Non, Mod = Moderate, G = Good.